6 / 38
Page 62
Notes:
allied
academies
Ann Biol Sci, 2017
ISSN: 2348-1927
August 23-24, 2017 | Toronto, Canada
Annual Conference on
MICROBIAL PATHOGENESIS, INFECTIOUS DISEASE,
ANTIMICROBIALS AND DRUG RESISTANCE
Background:
Candida glabrata
is pathogenic yeast with
several unique biological features and associated with an
increased incidence rate of candidiasis. It exhibits a great
degree of variation in its pathogenicity and antifungal
susceptibility.
Objectives:
Theaimof thepresent studywas toevaluate the in
vitro antifungal susceptibilities of the following six antifungal
drugs against clinical
C. glabrata
strains: amphotericin B
(AmB), ketoconazole (KTZ), fluconazole (FCZ), itraconazole
(ITZ), voriconazole (VCZ), and caspofungin (CASP).
Materials & Methods:
Forty clinical
C. glabrata
strains were
investigated using DNA sequencing. The in vitro antifungal
susceptibility was determined as described in clinical
laboratory standard institute (CLSI) documents (M27-A3 and
M27-S4).
Results:
The sequence analysis of the isolate confirmed
as
C. glabrata
and deposited on NCBI GenBank under the
accession number no. KT763084-KT763123. The geometric
mean MICs against all the tested strains were as follows, in
increasing order: CASP (0.17 g/mL), VCZ (0.67 g/mL), AmB
(1.1 g/mL), ITZ (1.82 g/mL), KTZ (1.85 g/mL), and FCZ (6.7
g/mL). The resistance rates of the isolates to CASP, FCZ, ITZ,
VZ, KTZ, and AmB were 5%, 10%, 72.5%, 37.5%, 47.5%, and
27.5%, respectively.
Conclusions:
These findings confirm that CASP, compared
to the other antifungals, is the potent agent for treating
candidiasis caused by
C. glabrata
. However, the clinical
efficacy of these novel antifungals remains to be determined.
Speaker Biography
Nasrin Amirrajab is working as Assistant Professor of Medical Mycology, Department of
Laboratory Sciences, School of Paramedicine/Health Research Institute, Infectious and
Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences,
Ahvaz, Iran.
e:
n_amirrajab@yahoo.comIn-vitro
activities of six antifungal drugs against
Candida glabrat
a isolates: An emerging pathogen
Nasrin Amirrajab
Ahvaz Jundishapur University of Medical Sciences, Iran
Nasrin Amirrajab, Arch Clin Microbiol, 8:5
DOI: 10.4172/1989-8436-C1-003